AddThis

Adams, Lipocine to develop new cough medicines

Related Content

No related items were found.

CHESTER, N.J. Lipocine and Adams Respiratory Therapeutics have entered in an agreement to develop new prescription adult cough products.

Under the terms of the agreement, Adams receives exclusive rights from Lipocine to develop and market multiple prescription adult cough products. Adams will be responsible for performing clinical development, regulatory submission, manufacture, and commercial operations. Lipocine will be responsible for completing the product development work.

Lipocine will have the opportunity to receive reimbursements and payments in exchange for completing development milestones. “Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments,” said Dr. Mahesh Patel, president and chief executive officer of Lipocine.

© 2014 Drug Store News. All Rights Reserved.